Abstract
Autoimmune myopathies (myositides) are strongly associated with malignancy. The link between myositis and cancer, originally noticed by Bohan and Peter in their classification in 1975 (1), has been evidenced by large population-based cohort studies and a recent meta-analysis. The numerous reports of cases in which the clinical course of myositis reflects that of cancer and the short delay between myositis and cancer onset support the notion that myositis may be an authentic paraneoplastic disorder. Thus, cancer-associated myositis raises the question of cancer as a cause rather than a consequence of autoimmunity. Among myositides, dermatomyositis and more recently, although to a lesser extent, immune-mediated necrotizing myopathies are the most documented forms associated with cancer. Interestingly, the current diagnostic approach for myositis is based on the identification of specific antibodies where each antibody determines specific clinical features and outcomes. Recent findings have shown that the autoantibodies anti-TIF1γ, anti-NXP2 and anti-HMGCR are associated with cancers in the course of myositis. Herein, we highlight the fact that the targets of these three autoantibodies involve cellular pathways that intervene in tumor promotion and we discuss the role of cancer mutations as autoimmunity triggers in adult myositis.
Introduction
The link between autoimmunity and cancer has become a topic of unceasing interest over the past decade. Although it is increasingly evident that the risk of cancer is augmented in patients affected by several types of autoimmune diseases (AID), the nature of the interplay between autoimmunity and cancer remains elusive (2–4). One important question here recalls the old egg-and-chicken dilemma: is the autoimmune background in AID a seedbed for cancer development or, alternatively, may cancer cause autoimmunity?
Rheumatic AID such as systemic lupus erythematosus, rheumatoid arthritis, or Sjögren syndrome promote cancer development after several years of chronic inflammation and also exposure to immunosuppressive drugs (2, 5, 6). In the case of lupus for instance, the broadness of cancer type spectrum is striking, including hematological—mostly virus induced—malignancies but also numerous kinds of solid tumors such as vulva, lung, thyroid, and liver cancer (7). Here, the risk of cancer cannot only be ascribed to the sole autoimmune status but also presumably to iatrogenic immunosuppression.
This view is counterbalanced by the examples of paraneoplastic neurological syndromes, systemic sclerosis, and myositis. Paraneoplastic neurological syndromes with anti-neuronal autoantibodies (aAbs) include a most illustrative example, i.e., anti-Hu encephalitis associated with small cell lung carcinoma (SCLC) (8). Anti-Hu aAbs recognize the HuD autoantigen normally restricted to neurons but ectopically expressed on SCLC cells (9). Expression of the immunogenic HuD molecule by SCLC elicits the production of anti-Hu aAb and CD8+ cytotoxic T cells, explaining the parallel clinical course of neurological symptoms and SCLC evolution and demonstrating the direct link between cancer and tissue-specific AID (10). Cancer-induced breakage of tolerance can also be caused by tumoral somatic mutations, as recently highlighted by the case of systemic sclerosis associated with anti-polymerase III (POL3) aAbs. The immunogenic peptides generated by POLR3 gene mutations induce a POL3-specific CD4+ T cell response with production of specific antibodies that secondarily target wild-type POL3 by epitope spreading (11).
This present review focuses on the forms of myositides, i.e., dermatomyositis (DM) and immune-mediated necrotizing myopathies (IMNMs) which have been identified as associated with cancer and represent a paradigm of cancer-associated AID.
DM, Risk of Cancer, and Diagnostic Contribution of Autoantibodies
Autoimmune myopathies or myositides constitute a heterogeneous group of severe acquired myopathies. They are characterized clinically by symmetrical proximal muscle weakness, associated or not with systemic features, and histologically by various levels of myofiber necrosis/regeneration and interstitial mononuclear infiltrates. Clinical and histopathological patterns define different diseases: polymyositis, DM, overlap myositis, sporadic inclusion-body myositis, and IMNM (12–17).
Dermatomyositis affects both adults and children among all ethnic groups with an unbalanced 1/2-sex-ratio in favor of women. Its annual incidence varies from 1.9 to 7.7 cases per million inhabitants according to data in the literature with a peak of frequency in 40–60-year-old adults and in 5–14-year-old children (13, 18). The appearance of specific cutaneous manifestations is typical of DM and is among its diagnostic criteria. Cutaneous manifestations typically consist of erythematous scaly papules over the metacarpophalangeal knuckles (Gottron’s papules) (Figure 1A); a symmetrical reddish-violet periorbital edema that predominates on the upper eyelids (heliotrope erythema) but may affect the rest of the face; lupus-like erythema which involves low neck (V sign) (Figure 1B), shoulders (shawl sign), extensor surfaces of the limbs, dorsal side of hands and fingers and scalp; poikiloderma of the upper trunk (Figure 1C); and centripetal flagellate erythema affecting the trunk and or proximal extremities (Figure 1D). Cutaneous manifestations of DM also include non-specific lesions such as (i) vascular lesions, i.e., periungual erythema with telangiectatic capillary loops, nail fold dilated capillaries visible to the naked eye, cuticular hypertrophy (Figures 1E,F), vasculitis, cutaneous necrosis, or Raynaud’s phenomenon, which are more prevalent in the course of juvenile dermatomyositis and (ii) several other dermatological features such as pruritus (present in 30% of DM), photosensitivity, mucinosis, and calcifications, which are more frequent in children rather than in adults, i.e., 30–70 versus 10%. Dermatological particularities of DM have been reported in several ethnic groups. In Afro-Caribbeans, edema of the face is usually predominant whereas in Eurasians, the Wong-type DM which mimicks a pytiriasis rubra pilaris seems to be more frequent (19).
Figure 1
Specific lesions of DM are histologically characterized by an interface dermatitis with basal layer vacuolar changes that are associated in various degrees with hyperkeratosis, epidermal atrophy, basement membrane thickening, upper dermal edema, pigmentary incontinence, mucine deposits, and light perivascular CD4+ T lymphocyte infiltrate of the superficial dermis (Figures 1G–I) (20).
Dermatological features usually precede muscle weakness by 3–6 months but may appear several years before. However, muscular manifestations may be absent, defining the amyopathic form of DM with an associated cancer rate, which is theoretically the same as classic DM (21, 22).
Diagnosis of DM is supported by serum creatine kinase (CK) elevation, which mirrors muscle lysis and by electromyographic data, but diagnosis is confirmed by muscle biopsy except for amyopathic DM. Histological examination of muscle tissue (Figure 2) typically shows perifascicular atrophy, necrotic and regenerative muscle fibers, septal and/or perivascular inflammatory cell infiltrate, and endomysial microangiopathy with membranolytic attack complex C5b-9 capillary staining that may also be present in cutaneous lesions. Although these capillary injuries have long been considered as indirect evidence of an initial endothelial target in DM, recent scientific findings demonstrate that capillary lesions might be non-specific in relationship to ischemia-reperfusion injury of perimysial arcade arteries (23). The role for interferons in DM pathogenesis is increasingly evident, since a typical interferon type 1 pathway signature was found in both muscle (24) and skin (25), with a correlation with disease activity (26).
Figure 2
The outcome of DM is variable with benign forms highly responsive to treatment and severe forms associated with cardiac or lung involvement and/or malignancies. In juvenile DM, cancer association is uncommon. Nonetheless, a poor prognosis may be due to the intensity of vasculitis and vascular damage that involves the skin and the digestive system. Calcifications on the areas around joints may also lead to severe functional impairment in children.
Interestingly, several dermatological manifestations of DM such as cutaneous necrosis, skin vasculitis or pruritus, or histological patterns such as leucocytoclastic vasculitis are reported to be associated with cancer whatever the ethnic group (27, 28). Conversely, several features seem to protect against cancer such as Afro-Caribbean ethnicity (29).
Globally, myositides are rare diseases and epidemiologic data remain scarce. Studies are limited by their retrospective character and small population size. Yet, since its first descriptions (30, 31), the association between cancer and myositis has been confirmed by several studies published between 1975 and 2012, reporting a global malignancy rate from 6.7 to 32% (32–35). Importantly, several studies also point to cancer as the main cause of death in cancer-associated myositis patients (34, 36, 37). Yet, it may be difficult to distinguish between cancer on the one hand, and myositis exacerbation and its complications on the other hand, as the actual cause of death. Most observations highlighted the short delay between the onset of myositis and the discovery of cancer. In some cases, cancer even preceded myositis, reinforcing the view that myositis might be the consequence rather than the cause of cancer and even leading to individualizing “cancer-associated myositis” in one classification in 2005 (14). Cancer risk is particularly established in DM. A recent meta-analysis confirmed adult (but not juvenile) DM as a risk-factor of cancer, with a standardized incident ratio (SIR) for occurrence of cancer of 5.5 [4.3–6.7], mostly peaking at 1 year around DM diagnosis (38). A limitation to previous studies, including those reviewed in this meta-analysis, is that the classification of myositis was essentially based on the widely used Bohan and Peter classification which tends to classify IMNM, overlap myositis, and polymyositis in a single category (1). Whereas this classification remains popular for its practical value in DM, progress in the definition of clinical, pathological, and serological patterns has led to newer classifications that are useful for the diagnosis of inclusion-body myositis (12), overlap myositis (14), or IMNM (13). In the light of these different existing classifications for myositis, a new unifying classification would provide a much-awaited tool.
The detection of myositis-specific aAbs (MSA) has proved most helpful in classifying the different forms and predicting the outcome of myositis. Indeed, in clinical practice, MSA define particular clinical ± histological patterns (39). In DM, anti-Mi-2 are classically associated with absence of cancer, sensitivity to treatment and, overall, good prognosis (40–42). Anti-melanoma differentiation antigen 5 (MDA-5) identifies a subgroup of DM patients with interstitial lung disease, necrotizing cutaneous lesions, skin ulcerations, and tender palmar papules while muscle signs are minimal (43–45). Anti-SAE (small ubiquitin-like modifier activating enzyme) has a low prevalence (1–4%) and patients have classic cutaneous signs of DM. Interestingly, a significant but low rate of cancer has been reported in this group (46–48). Anti-TIF1γ (transcriptional intermediary factor 1 gamma) is the leader of cancer-associated aAbs, with a rate of associated malignancy ranging from 60 to 80% of patients (49, 50). Anti-NXP2 (nuclear matrix protein 2) is another biomarker of risk of malignancy in adult patients, with a 30% rate of cancer among DM patients (51, 52).
Besides DM, IMNM is another form of myositis recently suggested to be associated with malignancy (53–55). IMNM may be subdivided in three groups: seronegative, anti-HMGCR (3-hydroxy-3-methylglutaryl-coenzyme-A-reductase), and anti-SRP (signal recognition particle). In contrast to anti-SRP positive patients, one study has recently suggested that, among IMNM, seronegative and anti-HMGCR positive patients have a significantly higher risk of cancer (56).
Cancer-Associated Myopathies According to Autoantibodies
DM with Anti-TIF1γ, the Leader in Cancer-Associated Myositis
Anti-TIF1γ was first described in 2006 as an antibody directed against a 155 kDa protein, especially in patients with DM (49, 57). This protein was rapidly identified as TIF1γ. Anti-TIF1γ aAbs scored positive in 20–30% of adult DM and 30–40% of juvenile DM with some differences according to geographical origin (39, 58). HLA DQA1*0301 was associated with anti-TIF1γ DM (49). The high prevalence of cancer was largely confirmed with a rate from 18 up to 80% of adult patients especially in the 2 years surrounding DM (22, 52, 59). A meta-analysis performed by Trallero-Araguás and colleagues estimated a 78% sensitivity and 89% specificity of these antibodies for diagnosing an associated cancer (50). Since 2001, age has been recognized as a risk factor for cancer among DM patients (33). Recently, two publications strengthened the role of advancing age in the increasing risk of cancer among adult anti-TIF1γ positive DM patients (60, 61).
No study found any predominance of one type of cancer; those occurring in adults with DM were generally comparable to those in the general population, stratified by age and sex (breast, lung, colorectal, bladder) as well as to some more rare cancers such as gastric or thymus cancer (59). Anti-TIF1γ DM associates classic but severe cutaneous signs with moderate muscular symptoms, frequent dysphagia but decreased systemic features compared to other DM (60). The specific clinical and histopathological features of anti-TIF1γ DM are summarized in Table 1. Regarding juvenile DM, no increased risk of cancer is observed (62). The median age of DM is 6.8 years of age. Anti-TIF1γ juvenile DM more often presents chronic or polycyclic courses associated with more severe prognosis and profuse cutaneous involvement (63).
Table 1
| Anti-TIF1γ dermatomyositis (DM) | Anti-NXP2 DM | Anti-HMGCR immune-mediated necrotizing myopathy | |
|---|---|---|---|
| Year of discovery of the aAb | 2006 (49, 57) | 1997 (64) | 2010 (65, 66) |
| Frequency of cancer association in adults | 60–80% (22, 52, 59) | 24–37.5% (60, 61, 67) | 12.9–36% (56, 68, 69) |
| Clinical features | |||
| Skin involvement | Extensive cutaneous signs | Mild skin involvement | Generally not |
| Poikiloderma | Frequency of calcinosis | ||
| Psoriasis-like lesions | |||
| Scaly erythema of the scalp | |||
| No calcinosis | |||
| Muscular involvement | Mild weakness | Mild to severe weakness | Mild to severe weakness |
| Myalgia | |||
| Frequency of distal weakness | Inconstant dysphagia | ||
| Frequent dysphagia | Myalgia, muscle atrophy | ||
| Frequent dysphagia mild to severe | |||
| Other characteristics | Peripheral edema | Peripheral edema | High frequency of statin exposure (65, 66, 71) |
| Decreased risk of Raynaud phenomenon, arthralgia, and interstitial lung disease (60) | Low frequency of interstitial lung disease (61, 70) | ||
| Histological pattern | Dense C5b-9 deposits on capillaries | Perivascular inflammation | Necrosis |
| Presence of vacuolated fibers | Perifascicular atrophy | Muscle fiber regeneration | |
| Overexpression of MHC class I | Necrosis in patient with peripheral edema (70) | Atrophic fibers | |
| Perifascicular atrophy | Little or no inflammatory infiltration C5b-9 deposition (13, 72) | ||
| Necrotic/regenerating fibers (59) | |||
| Target of the aAbs | |||
| Name | Transcriptional intermediary factor 1 gamma | Nuclear matrix protein 2 or microrchidia 3 (MORC3) | 3-hydroxy-3-methylglutaryl-coenzyme-A-reductase |
| Protein expression | Ubiquitous | Ubiquitous | Ubiquitous |
| Immune cells at high level | Liver | ||
| Subcellular locations | Nucleus | Nucleus | Endoplasmic reticulum |
| Cytosol in part | Peroxisome | ||
| Role | TGFβ pathway | Chromatin remodeling | Limiting enzyme for cholesterol synthesis and other mevalonate-dependent pathways (81–83) |
| Mitosis | DNA repair | ||
| Embryonic development | Epigenetic regulation | ||
| DNA repair | Cell regulation | ||
| Erythropoiesis | Activation of p53 | ||
| Innate immunity | Calcium homeostasis | ||
| (73–76) | Bone remodeling (77–80) | ||
Characteristics of anti-TIF1γ, anti-NXP2, and anti-HMGCR myositis.
DM with Anti-NXP2, the Second Actor in Cancer-Associated Myositis
A novel aAb directed against a 140 kDa protein was found in a 1997 cohort of juvenile DM and named anti-MJ (64). The 140 kDa protein was next identified as NXP2, also known as MORC3 (84). Anti-NXP2 aAbs are present in 22–25% of juvenile DM patients and in 1–17% of adults with DM, depending on the method of detection (61, 70). Forms of myositides other than DM may occasionally be associated with anti-NXP2 (67, 84). Cancer was detected in 24–37.5% of adults who scored positive for anti-NXP2 in several retrospective series (60, 61, 67). As for anti-TIF1γ DM, no specific type of tumor was mentioned. Clinical manifestations are partially distinct from anti-TIF1γ DM (Table 1). Indeed, classic cutaneous features are less severe but there is a higher prevalence of calcinosis (70). In addition, muscular involvement is constant and more severe. Similarities between anti-TIF1γ and anti-NXP2 include dysphagia and prevalence of peripheral edema (61, 70). Interstitial lung disease has only been reported in one cohort (85) and Raynaud’s phenomenon is found in 20% of cases (64, 85).
In children, the median age at onset has been calculated at 5.8 years of age (58). Two series found an increased risk of calcinosis in children and a high prevalence of severe muscular involvement with functional disabilities, muscle cramps, and dysphagia but no cancer (Table 1) (39, 51).
IMNMs, New Players in Cancer-Associated Myositis?
Immune-mediated necrotizing myopathies are a recently described entity, based on specific histological pattern with poor inflammatory infiltrate and presence of significant necrotizing and regenerative fibers (13, 72). As mentioned above, three IMNM subsets have been identified according to serologic status: anti-SRP, anti-HMGCR, or negative serology. Anti-HMGCR and seronegative IMNMs seem to be associated with a higher risk of cancer, with a SIR score of 2.79 and 8.35, respectively (56). Between 13 and 36% of anti-HMGCR positive patients have an associated cancer (56, 68, 69). A genetic study found that HLA-DRB1*11:01 is associated with a higher risk of anti-HMGCR IMNM in both white American and African American adult populations, whereas HLA-DRB1*07:01 seem to be associated with a risk of anti-HMGCR myositis in small series of children (86, 87).
Anti-HMGCR aAbs were discovered in 2010 in a group of patients who developed myositis after exposure to statins, without resolution by stopping statins (65, 66). Histological features corresponded to IMNM (88–90). While the association with statins was confirmed in recent studies, it involved a wide range between 37 and 94% of patients (56, 91). Thus, statins are not necessarily required to develop anti-HMGR myositis. Clinically, patients present severe and acute muscle weakness, dramatically elevated CK level, but extra-muscular disorders are uncommon (65, 66, 71). Anti-HMGCR aAbs have also been identified in the sera of juvenile myositis, without exposure either to statins or cancer. Clinical features in children may wrongly shift toward muscular dystrophy (92).
Targets of Cancer-Associated Autoimmune Response in Myositis
Intriguingly, all three aAb targets in cancer-associated myositis are involved to some extent in cancer pathogenesis.
TIF1γ, Encoded by the TRIM33 Gene
TIF1γ, also known as ecto, RETfused7, or TRIM33, was discovered in 1999 and identified as the third member of the TIF1 protein (after TIF1α and TIF1β) (73). These three proteins belong to the TRIM (tripartite motif) protein family defined by a particular RING-finger domain (93). TIF1 proteins are a subfamily characterized by several domains from 3′ to 5′, including the RING-finger domain, 1 or 2B-boxes, a coiled-coil domain, a plant homeodomain (PHD), and a bromodomain (94). They are involved in multiple critical biological processes. TIF1γ is particularly known for being involved in embryonic development, hematopoiesis, mitosis and cycle regulation, DNA repair, innate and adaptive immunity, osteoblast differentiation, viral transcription, and oncogenesis in case of dysregulation. TIF1γ can exert its role as an E3-ubiquitin ligase, as a histone-binding protein or by sumoylating proteins.
The main interacting pathways of TIF1γ are the TGF-β canonical (Smad4-dependent) and non-canonical (Smad4-independent) pathways (95–97). In the canonical pathway, TIF1γ acts either as a repressor (via ubiquitination), a competitor or a partner of Smad4, depending on the cellular context (96). In the canonical TGF-β pathway, the activation of the TGF-β receptor leads to the recruitment of RSmad (Smad 2 or 3) and phosphorylation allows the formation of a RSmad/Smad4 complex, which next enters the nucleus to activate the transcription of targeted genes. During mammalian embryonic development, TIF1γ plays a major role in patterning and polarizing embryonic cells before gastrulation by inhibiting Nodal/Smad4 signaling, which promotes endodermic proliferation (98). Later in embryonic development, Smad4 and TIF1γ cooperate or act redundantly to promote both proliferation and differentiation of neural stem cells and palate development (99, 100). It has been shown that TIF1γ participates in the differentiation of stem cells in collaboration with Smad4, by direct interaction with histone via PHD–bromodomain leading to the assembling of Smad4/Smad2–3 complex on targeted genes (101). In adult tissues, TIF1γ promotes the terminal differentiation of mammary gland and lactation by antagonization of Smad4 (102), supports both osteoblast proliferation and differentiation under stimulation of bone morphogenetic proteins (BMP) via the activation of a particular RSmad complex (Smad1/5) (103), regulates granulopoiesis in mice (104), and participates in the development of iNKT cells (105). During erythropoiesis, Smad4 and TIF1γ competitively bind to phosphorylated SMad2/3 (RSmad) in response to TGF-β to promote the proliferation and maturation of erythroblasts (106, 107). Otherwise, TIF1γ is involved in the balance between lymphoid and myeloid lineage and protects hematopoietic stem cells from aging (108), through TAL1 and PU1 DNA-binding protein, whose transcriptional activity depend on TGF-β (109, 110). TIF1γ has many other functions in cells, mediated by different pathways and functions. Regarding the innate immune system, TIF1γ directly represses the transcription of the interferon-b gene (ifnb) at late phase of macrophage activation (74). Also, it binds multiple chromatin sites in monocyte to promote production of macrophage, binds other chromatin sites in mature macrophage to regulate the responses after toll-like receptor (TLR) activation by lipo-polysaccharide (LPS) (111), and is directly involved in proteasome activation via the ubiquitination of DHX33 (112). TIF1γ also has many roles in cell homeostasis; TIF1γ is strongly involved in antiproliferative cellular effect by (i) mediating ubiquitination and then the degradation of LIM-domain-binding protein which is involved in the transcription of cycle activator genes (113) and (ii) interaction with APC/C (anaphase-promoting complex/cyclosome) to promote the alignment and stability of chromosomes during mitosis and to prevent abnormal metaphase–anaphase transition (75, 76). Moreover, TIF1γ is largely involved in DNA repair by recruiting different proteins promoting chromatin relaxation and repair (114, 115). Next, TIF1γ is a strong tumor suppressor by preventing β-catenin degradation (116), epithelial-to-mesenchymal transition (117, 118), and by regulation of the chromatin (119, 120). The role of TIF1γ as a tumor suppressor has been directly shown in chronic myelomonocytic leukemia (121), pancreatic tumor (122–124), hepatocellular carcinoma (125), renal cell carcinoma (126), and non-small cell lung cancer (127), where TIF1γ decreased expression or inactivation promotes proliferation and probably epithelial-to-mesenchymal transition (97–104). Paradoxically, overexpression of TIF1γ is involved in oncogenesis notably in breast cancer, where TIF1γ interferes with TGF-β to promote poorer prognosis (128). Moreover, hyper-expression of TIF1γ has been shown in a significant proportion of colorectal adenocarcinomas (129).
NXP2, Encoded by the MORC3 Gene
MORC3 (microrchidia3) is a nuclear protein which belongs to a highly conserved nuclear matrix protein family which has recently been identified (77). Four MORC members have been identified and are characterized by three common structural domains (ATPase domain, Zinc finger domain, and coiled-coil domain) involved in chromatin remodeling and epigenetic regulation (77). MORC3 includes two other domains, a nuclear matrix binding site and an RNA binding site, essential for the regulation of transcription (78). Its mRNA expression is relatively ubiquitous but the expression of MORC3 protein is particularly elevated in immune cells (78, 79). MORC3 plays several critical roles in cell regulation, illustrated by an early death at birth or day 1 in MORC3 knockout mice (130). MORC3 promotes the activation of p53, a tumor suppressor inducing cellular senescence in response to oncogenic factors and supports the architecture of the nucleus (78, 130). The ATPase domain of MORC3 interacts with the coiled-coil domain to form homodimers that can bind DNA (131). Zinc finger is implicated in the nucleus localization and binds MORC3 to histone (132). These two mechanisms seem to be involved in DNA repair and epigenetic regulation (77, 80). MORC3 interacts with ROR1, a tyrosine kinase involved in pre-B cell receptor signaling pathway promoting cell proliferation (133). Finally, MORC3 plays a role in the transduction of calcium homeostasis regulator and is involved in bone remodeling (134).
HMGCR, Encoded by the HMGCR Gene
HMGCR is a limiting enzyme from the cholesterol biosynthetic chain, catalyzing the reduction reaction of HMGCoA to mevalonate (81). This enzyme has a large transmembrane domain in the endoplasmic reticular membrane and the harbored cytosolic N and C terminal domain. The catalytic domain is in the C-terminal domain (82, 83). This catalytic domain is the target of both statins and specific autoantibodies. Interestingly, it has been recently shown that its functions were indirectly crucial in many pathways. Indeed, HMGCR positively regulates the growth and migration of glioblastoma cells and could play a role in the metastatic capacities of tumoral cells, as well as other enzymes involved in lipidic metabolism (135). The role of HMGCR and the mevalonate pathway in oncogenesis has been suspected for two decades and cases of tumors have been reported to exhibit higher level and activity of HMGCR (136, 137). In 2010, Clendening et al. (138) confirmed this hypothesis by showing that the dysregulation of HMGCR promotes transformation of normal breast epithelial cells and growth of transformed cells (138). Moreover, different levels of HMGCR are associated with different response to radiotherapy in bladder cancer (139) and upregulation of HMGCR is also known to promote proliferation and migration of malignant cells in both glioblastoma and gastric cancer (135, 140). In vitro inhibition of HMGCR performed by specific miRNA limits proliferation, invasion, and metastasis process of breast cancer cells (141).
TIF1γ, NXP2, and HMGCR: Targets of an Antitumoral Response?
In the model proposed by Joseph and colleagues in systemic sclerosis, the immune response directed against POL3 was initially an antitumor immune response. Oncogenesis results from random and additive mutations on several genes some of which are involved in mitotic checkpoint, DNA repair, or differentiation, under the effect of viruses, oncogenes, or radiation. Later, tumoral cells can over-express, ectopically express, or express mutated forms of distinct proteins. The immune system may recognize these newly synthetized forms as neoantigens, which may ultimately lead to T cell and B cell responses (142, 143).
In many human cancers, TIF1γ is considered as a tumor suppressor by inhibiting the TGF-β pathway. HMGCR also seems to be involved to some extent in oncogenesis through its role in metabolic pathways. Today, NXP2 is not directly known to be involved in cancer but it interacts with the well documented p53 tumor suppressor. Therefore, the targets of these three MSA appear to be proteins involved in cellular pathways that intervene in tumor promotion. Thus, it is reasonable to hypothesize that somatic mutations of TIF1γ, NXP2, or HMGCR genes in tumors may provoke a specific antitumoral immune response which may secondarily extend to the target organs of myositis (muscle, skin) by cross-reactivity and/or a process of epitope spreading (Figure 3). It is tempting to speculate that absence of cancer in some myositis patients may result from an efficacious antitumoral immune response: in this view, myositis might be the immunological price to pay for tumor eradication.
Figure 3
The hypothesis developed herein implies that the abovementioned antitumoral response provokes/sustains myositis. How this response could promote myositis is unclear. Indeed, the three TIF1γ, NXP-2, and HMGCR proteins are ubiquitously expressed, raising the question of how they could be muscle/skin-specific. In this regard, it should be remembered that most if not all MSAs, associated with cancer or not, are specific for ubiquitously expressed, intracellular proteins such as t-RNA synthetases, MDA-5, and signal recognition particles.
Some elements support the direct pathogenicity of aAbs in some forms of myositis. For instance, aAb level correlates with clinical evolution in IMNM (72, 144–146). The pathogenic effect of aAbs is particularly real for anti-HMGCR aAb. Indeed, Arouche-Delaperche and colleagues recently demonstrated that anti-HMGCR aAbs promoted muscle atrophy and impaired regeneration and expression of inflammatory cytokines (147). A similar effect could be expected for anti-TIF1γ and NXP2 aAbs. TIF1γ has been shown to be over-expressed in regenerating muscle (148), which could explain the recognition of TIF1γ in muscle by aAb.
The Therapeutic Dilemma of Cancer-Associated Myositis
Most myositis clinical trials exclude patients with cancer, limiting the spectrum of our therapeutic knowledge. While beneficial for treating myositis, immunosuppression is of difficult use in the presence of cancer. Reciprocally, myositis alters the patient’s condition and complicates the therapeutic strategy, i.e., administering antitumoral drugs or performing surgery. Guidelines will be required to help manage patients in this context. The hypothesis of myositis triggered by cancer, rather than the opposite, supports a therapeutic strategy of performing an active antitumoral treatment compatible with the patient’s myositis status. Among new cancer therapies, immune checkpoint inhibitors may expose the patient to an exacerbation of autoimmunity that may yield a myositis flare. Since aAbs may be directly involved in myositis pathogenesis, therapeutic trials evaluating plasma exchanges are welcome.
Conclusion
Taken together, available data point to a unicist view of cancer-associated myositis, in which AID may result from an antitumoral response. This response may be triggered by mutations, overexpression, or posttranslational modification of the autoantigen in tumor. Elucidating these mechanisms will provide strong clues to better understand the potential role of cancer as a cause of autoimmunity.
Statements
Author contributions
The first version of this review was written by AA and NC. OB revised it critically for important intellectual content. All authors approved the version to be published.
Acknowledgments
We are grateful to Nikki Sabourin-Gibbs (Rouen University Hospital) for her help in editing the manuscript. We would like to thank Marie Beylot-Barry (Bordeaux University Hospital) for providing clinical images, and Philippe Courville (Rouen University Hospital) and François-Jérôme Authier (Henri Mondor Hospital-APHP) for providing histological images. We also express our gratitude to François-Jérôme Authier, Yves Allenbach (Pitié Salpêtrière Hospital-APHP), and Alain Meyer (Strasbourg University Hospital) for their critical reading of the manuscript and helpful suggestions.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
BohanAPeterJB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med (1975) 292(7):344–7.10.1056/NEJM197502132920706
2
ZintzarasEVoulgarelisMMoutsopoulosHM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med (2005) 165(20):2337–44.10.1001/archinte.165.20.2337
3
ShahAACasciola-RosenLRosenA. Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol (2015) 67(2):317–26.10.1002/art.38928
4
EgizianoGBernatskySShahAA. Cancer and autoimmunity: harnessing longitudinal cohorts to probe the link. Best Pract Res Clin Rheumatol (2016) 30(1):53–62.10.1016/j.berh.2016.03.001
5
BernatskySRamsey-GoldmanRJosephLBoivinJFCostenbaderKHUrowitzMBet alLymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis (2014) 73(1):138–42.10.1136/annrheumdis-2012-202099
6
LiangYYangZQinBZhongR. Primary Sjogren’s syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis (2014) 73(6):1151–6.10.1136/annrheumdis-2013-203305
7
BernatskySRamsey-GoldmanRLabrecqueJJosephLBoivinJFPetriMet alCancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun (2013) 42:130–5.10.1016/j.jaut.2012.12.009
8
HonnoratJAntoineJC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis (2007) 2:22.10.1186/1750-1172-2-22
9
ManleyGTSmittPSDalmauJPosnerJB. Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol (1995) 38(1):102–10.10.1002/ana.410380117
10
PignoletBSGebauerCMLiblauRS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology (2013) 2(12):e27384.10.4161/onci.27384
11
JosephCGDarrahEShahAASkoraADCasciola-RosenLAWigleyFMet alAssociation of the autoimmune disease scleroderma with an immunologic response to cancer. Science (2014) 343(6167):152–7.10.1126/science.1246886
12
GriggsRCAskanasVDiMauroSEngelAKarpatiGMendellJRet alInclusion body myositis and myopathies. Ann Neurol (1995) 38(5):705–13.10.1002/ana.410380504
13
HoogendijkJEAmatoAALeckyBRChoyEHLundbergIERoseMRet al119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord (2004) 14(5):337–45.10.1016/j.nmd.2004.02.006
14
TroyanovYTargoffINTremblayJLGouletJRRaymondYSenecalJL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) (2005) 84(4):231–49.10.1097/01.md.0000173991.74008.b0
15
LundbergIE. New ways to subclassify patients with myositis. J Intern Med (2016) 280(1):4–7.10.1111/joim.12515
16
LundbergIEMillerFWTjärnlundABottaiM. Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med (2016) 280(1):39–51.10.1111/joim.12524
17
SimonJPMarieIJouenFBoyerOMartinetJ. Autoimmune myopathies: where do we stand?Front Immunol (2016) 7:234.10.3389/fimmu.2016.00234
18
OddisCVConteCGSteenVDMedsgerTA. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol (1990) 17(10):1329–34.
19
FrancèsCBessisD. Dermatomyosite. Manifestations dermatologiques des connectivites, vasculites et affections systémiques apparentées. 2nd Ed. Paris: Springer (2012). p. 1–15.
20
McKeePCalonjeEGranterS. Pathology of the Skin with Clinical Correlations. 3rd ed. Philadelphia: Elsevier/Mosby (2005).
21
SontheimerRD. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol (1999) 11(6):475–82.10.1097/00002281-199911000-00005
22
IaccarinoLGhirardelloABettioSZenMGattoMPunziLet alThe clinical features, diagnosis and classification of dermatomyositis. J Autoimmun (2014) 4(8–49):122–7.10.1016/j.jaut.2013.11.005
23
GitiauxCKostallariELafustePAuthierFJChristovCGherardiRK. Whole microvascular unit deletions in dermatomyositis. Ann Rheum Dis (2013) 72(3):445–52.10.1136/annrheumdis-2012-201822
24
GreenbergSAPinkusJLPinkusGSBurlesonTSanoudouDTawilRet alInterferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol (2005) 57(5):664–78.10.1002/ana.20464
25
WongDKeaBPesichRHiggsBWZhuWBrownPet alInterferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One (2012) 7(1):e29161.10.1371/journal.pone.0029161
26
HuardCGullàSVBennettDVCoyleAJVleugelsRAGreenbergSA. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis. Br J Dermatol (2017) 176(5):1224–30.10.1111/bjd.15006
27
HungerREDürrCBrandCU. Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology (2001) 202(2):123–6.10.1159/000051611
28
BurnoufMMahéEVerpillatPDescampsVLebrun-VignesBPicard-DahanCet al[Cutaneous necrosis is predictive of cancer in adult dermatomyositis]. Ann Dermatol Venereol (2003) 130(3):313–6.
29
TersiguelACLonguevilleCBeltanEVincentTTressièresBCordelN. [Prevalence of cancer in the Afro-Caribbean population presenting dermatomyositis and anti-synthetase syndrome: a preliminary study conducted at Pointe-à-Pitre University Hospital, 2000-2012]. Ann Dermatol Venereol (2014) 141(10):575–80.10.1016/j.annder.2014.04.112
30
KankeleitH. Über primaire nichteitrige polymyositis. Dtsch Arch Klin Med (1916) 120:335–9.
31
StertzG. Polymyositis. Berl Klin Wochenschau (1916) 53:489.
32
HillCLZhangYSigurgeirssonBPukkalaEMellemkjaerLAirioAet alFrequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet (2001) 357(9250):96–100.10.1016/S0140-6736(00)03540-6
33
StocktonDDohertyVRBrewsterDH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer (2001) 85(1):41–5.10.1054/bjoc.2001.1699
34
AndrásCPonyiAConstantinTCsikiZSzekaneczESzodorayPet alDermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol (2008) 35(3):438–44.
35
ZahrZABaerAN. Malignancy in myositis. Curr Rheumatol Rep (2011) 13(3):208–15.10.1007/s11926-011-0169-7
36
AirioAPukkalaEIsomäkiH. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol (1995) 22(7):1300–3.
37
WakataNKuriharaTSaitoEKinoshitaM. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol (2002) 41(11):729–34.10.1046/j.1365-4362.2002.01648.x
38
YangZLinFQinBLiangYZhongR. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol (2015) 42(2):282–91.10.3899/jrheum.140566
39
BetteridgeZMcHughN. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med (2016) 280(1):8–23.10.1111/joim.12451
40
GhirardelloAZampieriSIaccarinoLTarriconeEBendoRGambariPFet alAnti-Mi-2 antibodies. Autoimmunity (2005) 38(1):79–83.10.1080/08916930400022681
41
Selva-O’CallaghanALabrador-HorrilloMSolans-LaqueRSimeon-AznarCPMartínez-GómezXVilardell-TarrésM. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum (2006) 55(5):791–8.10.1002/art.22237
42
ChinoyHFertigNOddisCVOllierWECooperRG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis (2007) 66(10):1345–9.10.1136/ard.2006.068502
43
FiorentinoDChungLZwernerJRosenACasciola-RosenL. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol (2011) 65(1):25–34.10.1016/j.jaad.2010.09.016
44
HallJCCasciola-RosenLSamedyLAWernerJOwoyemiKDanoffSKet alAnti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) (2013) 65(8):1307–15.10.1002/acr.21992
45
SatoSKuwanaMFujitaTSuzukiY. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol (2013) 23(3):496–502.10.1007/s10165-012-0663-4
46
BetteridgeZEGunawardenaHChinoyHNorthJOllierWECooperRGet alClinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis (2009) 68(10):1621–5.10.1136/ard.2008.097162
47
MuroYSugiuraKAkiyamaM. Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity (2013) 46(4):279–84.10.3109/08916934.2012.755958
48
GeYLuXShuXPengQWangG. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Sci Rep (2017) 7(1):188.10.1038/s41598-017-00240-6
49
TargoffINMamyrovaGTrieuEPPerurenaOKoneruBO’HanlonTPet alA novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum (2006) 54(11):3682–9.10.1002/art.22164
50
Trallero-AraguásERodrigo-PendásJSelva-O’CallaghanAMartínez-GómezXBoschXLabrador-HorrilloMet alUsefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum (2012) 64(2):523–32.10.1002/art.33379
51
GunawardenaHWedderburnLRChinoyHBetteridgeZENorthJOllierWEet alAutoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum (2009) 60(6):1807–14.10.1002/art.24547
52
FiorentinoDFChungLSChristopher-StineLZabaLLiSMammenALet alMost patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum (2013) 65(11):2954–62.10.1002/art.38093
53
BasharatPLahoutiHAMammenALPinal-FernandezIBichileTLloydTEet alDiabetes and atorvastatin are potential risk factors for statin-associated myopathy with autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase. American College of Rheumatology Meeting 2014. Boston, USA (2014).
54
LimayeVBundellCHollingsworthPRojana-UdomsartAMastagliaFBlumbergsPet alClinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve (2015) 52(2):196–203.10.1002/mus.24541
55
TiniakouEMammenAL. Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol (2015) 52(1):20–33.10.1007/s12016-015-8511-x
56
AllenbachYKeraenJBouvierAMJoosteVChamptiauxNHervierBet alHigh risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain (2016) 139(Pt 8):2131–5.10.1093/brain/aww054
57
KajiKFujimotoMHasegawaMKondoMSaitoYKomuraKet alIdentification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) (2007) 46(1):25–8.10.1093/rheumatology/kel161
58
RiderLGNistalaK. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med (2016) 280(1):24–38.10.1111/joim.12444
59
HidaAYamashitaTHosonoYInoueMKaidaKKadoyaMet alAnti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology (2016) 87(3):299–308.10.1212/WNL.0000000000002863
60
FiorentinoDFKuoKChungLZabaLLiSCasciola-RosenL.Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol (2015) 72(3):449–55.10.1016/j.jaad.2014.12.009
61
FujimotoMWatanabeRIshitsukaYOkiyamaN. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol (2016) 28(6):636–44.10.1097/BOR.0000000000000329
62
GunawardenaHWedderburnLRNorthJBetteridgeZDunphyJChinoyHet alClinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) (2008) 47(3):324–8.10.1093/rheumatology/kem359
63
HabersGEHuberAMMamyrovaGTargoffINO’HanlonTPAdamsSet alBrief report: association of myositis autoantibodies, clinical features, and environmental exposures at illness onset with disease course in juvenile myositis. Arthritis Rheumatol (2016) 68(3):761–8.10.1002/art.39466
64
CeribelliAFrediMTaraborelliMCavazzanaIFranceschiniFQuinzaniniMet alAnti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther (2012) 14(2):R97.10.1186/ar3822
65
Christopher-StineLCasciola-RosenLAHongGChungTCorseAMMammenAL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum (2010) 62(9):2757–66.10.1002/art.27572
66
MammenALChungTChristopher-StineLRosenPRosenADoeringKRet alAutoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum (2011) 63(3):713–21.10.1002/art.30156
67
IchimuraYMatsushitaTHamaguchiYKajiKHasegawaMTaninoYet alAnti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis (2012) 71(5):710–3.10.1136/annrheumdis-2011-200697
68
BasharatPChristopher-StineL. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep (2015) 17(12):72.10.1007/s11926-015-0548-6
69
KadoyaMHidaAHashimoto MaedaMTairaKIkenagaCUchioNet alCancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol Neuroimmunol Neuroinflamm (2016) 3(6):e290.10.1212/NXI.0000000000000290
70
RogersAChungLLiSCasciola-RosenLFiorentinoDF. The cutaneous and systemic findings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken) (2017).10.1002/acr.23210
71
AllenbachYBenvenisteO. [Autoantibody profile in myositis]. Rev Med Interne (2013) 35(7):437–43.10.1016/j.revmed.2013.12.006
72
AllenbachYBenvenisteO. Acquired necrotizing myopathies. Curr Opin Neurol (2013) 26(5):554–60.10.1097/WCO.0b013e328364e9d9
73
VenturiniLYouJStadlerMGalienRLallemandVKokenMHet alTIF1gamma, a novel member of the transcriptional intermediary factor 1 family. Oncogene (1999) 18(5):1209–17.10.1038/sj.onc.1202655
74
FerriFParcelierAPetitVGallouetASLewandowskiDDallozMet alTRIM33 switches off Ifnb1 gene transcription during the late phase of macrophage activation. Nat Commun (2015) 6:8900.10.1038/ncomms9900
75
SedgwickGGTownsendKMartinAShimwellNJGrandRJStewartGSet alTranscriptional intermediary factor 1γ binds to the anaphase-promoting complex/cyclosome and promotes mitosis. Oncogene (2013) 32(39):4622–33.10.1038/onc.2012.501
76
PommierRMGoutJVincentDFAlcarazLBChuvinNArfiVet alTIF1γ suppresses tumor progression by regulating mitotic checkpoints and chromosomal stability. Cancer Res (2015) 75(20):4335–50.10.1158/0008-5472.CAN-14-3426
77
LiDQNairSSKumarR. The MORC family: new epigenetic regulators of transcription and DNA damage response. Epigenetics (2013) 8(7):685–93.10.4161/epi.24976
78
KimuraYSakaiFNakanoOKisakiOSugimotoHSawamuraTet alThe newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains. J Biol Chem (2002) 277(23):20611–7.10.1074/jbc.M201440200
79
SuAIWiltshireTBatalovSLappHChingKABlockDet alA gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A (2004) 101(16):6062–7.10.1073/pnas.0400782101
80
HongGQiuHWangCJadhavGWangHTicknerJet alThe emerging role of MORC family proteins in cancer development and bone homeostasis. J Cell Physiol (2017) 232(5):928–34.10.1002/jcp.25665
81
DurrIFRudneyH. The reduction of beta-hydroxy-beta-methyl-glutaryl coenzyme A to mevalonic acid. J Biol Chem (1960) 235:2572–8.
82
RoitelmanJSimoniRD. Distinct sterol and nonsterol signals for the regulated degradation of 3-hydroxy-3-methylglutaryl-CoA reductase. J Biol Chem (1992) 267(35):25264–73.
83
StormoCKringenMKGrimholtRMBergJPPiehlerAP. A novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) splice variant with an alternative exon 1 potentially encoding an extended N-terminus. BMC Mol Biol (2012) 13:29.10.1186/1471-2199-13-29
84
EspadaGMaldonado CoccoJAFertigNOddisCV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol (2009) 36(11):2547–51.10.3899/jrheum.090461
85
IshikawaAMuroYSugiuraKAkiyamaM. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology (Oxford) (2012) 51(7):1181–7.10.1093/rheumatology/kes033
86
MammenALGaudetDBrissonDChristopher-StineLLloydTELeffellMSet alIncreased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) (2012) 64(8):1233–7.10.1002/acr.21671
87
KishiTRiderLGPakKBarillas-AriasLHenricksonMMcCarthyPLet alAnti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies are associated with DRB1*07:01 and severe myositis in pediatric myositis patients. Arthritis Care Res (Hoboken) (2017) 69(7):1088–94.10.1002/acr.23113
88
Grable-EspositoPKatzbergHDGreenbergSASrinivasanJKatzJAmatoAA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve (2010) 41(2):185–90.10.1002/mus.21486
89
AllenbachYDrouotLRigoletACharuelJLJouenFRomeroNBet alAnti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) (2014) 93(3):150–7.10.1097/MD.0000000000000028
90
WatanabeYSuzukiSNishimuraHMurataKYKurashigeTIkawaMet alStatins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan. Medicine (Baltimore) (2015) 94(4):e416.10.1097/MD.0000000000000416
91
BerguaCChiavelliHSimonJPBoyerOJouenFStenzelWet alImmune-mediated necrotizing myopathy. Z Rheumatol (2016) 75(2):151–6.10.1007/s00393-015-0029-3
92
LiangWCUruhaASuzukiSMurakamiNTakeshitaEChenWZet alPediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies. Rheumatology (Oxford) (2017) 56(2):287–93.10.1093/rheumatology/kew386
93
HatakeyamaS. TRIM proteins and cancer. Nat Rev Cancer (2011) 11(11):792–804.10.1038/nrc3139
94
ReymondAMeroniGFantozziAMerlaGCairoSLuziLet alThe tripartite motif family identifies cell compartments. EMBO J (2001) 20(9):2140–51.10.1093/emboj/20.9.2140
95
AgricolaERandallRAGaarenstroomTDupontSHillCS. Recruitment of TIF1γ to chromatin via its PHD finger-bromodomain activates its ubiquitin ligase and transcriptional repressor activities. Mol Cell (2011) 43(1):85–96.10.1016/j.molcel.2011.05.020
96
AndrieuxGFattetLLe BorgneMRimokhRThéretN. Dynamic regulation of Tgf-B signaling by Tif1γ: a computational approach. PLoS One (2012) 7(3):e33761.10.1371/journal.pone.0033761
97
DupontSInuiMNewfeldSJ. Regulation of TGF-β signal transduction by mono- and deubiquitylation of Smads. FEBS Lett (2012) 586(14):1913–20.10.1016/j.febslet.2012.03.037
98
MorsutLYanKPEnzoEAragonaMSoligoSMWendlingOet alNegative control of Smad activity by ectodermin/Tif1gamma patterns the mammalian embryo. Development (2010) 137(15):2571–8.10.1242/dev.053801
99
FalkSJoostenEKaartinenVSommerL. Smad4 and Trim33/Tif1γ redundantly regulate neural stem cells in the developing cortex. Cereb Cortex (2014) 24(11):2951–63.10.1093/cercor/bht149
100
LaneJYumotoKAzharMNinomiya-TsujiJInagakiMHuYet alTak1, Smad4 and Trim33 redundantly mediate TGF-β3 signaling during palate development. Dev Biol (2015) 398(2):231–41.10.1016/j.ydbio.2014.12.006
101
MassaguéJXiQ. TGF-β control of stem cell differentiation genes. FEBS Lett (2012) 586(14):1953–8.10.1016/j.febslet.2012.03.023
102
HeslingCLopezJFattetLGonzaloPTreilleuxIBlanchardDet alTif1γ is essential for the terminal differentiation of mammary alveolar epithelial cells and for lactation through SMAD4 inhibition. Development (2013) 140(1):167–75.10.1242/dev.085068
103
GuoJQinWXingQGaoMWeiFSongZet alTRIM33 is essential for osteoblast proliferation and differentiation via BMP pathway. J Cell Physiol (2017) 232(11):3158–69.10.1002/jcp.25769
104
ChrétienMLLegougeCMartinRZHammannATradMAucagneRet alTrim33/Tif1γ is involved in late stages of granulomonopoiesis in mice. Exp Hematol (2016) 44(8):727–39.e6.10.1016/j.exphem.2016.04.009
105
DoisneJMBartholinLYanKPGarciaCNDuarteNLe LuduecJBet aliNKT cell development is orchestrated by different branches of TGF-beta signaling. J Exp Med (2009) 206(6):1365–78.10.1084/jem.20090127
106
HeWDornDCErdjument-BromageHTempstPMooreMAMassaguéJ. Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell (2006) 125(5):929–41.10.1016/j.cell.2006.03.045
107
BaiXTrowbridgeJJRileyELeeJADiBiaseAKaartinenVMet alTiF1-gamma plays an essential role in murine hematopoiesis and regulates transcriptional elongation of erythroid genes. Dev Biol (2013) 373(2):422–30.10.1016/j.ydbio.2012.10.008
108
QuéréRSaint-PaulLCarmignacVMartinRZChrétienMLLargeotAet alTif1γ regulates the TGF-β1 receptor and promotes physiological aging of hematopoietic stem cells. Proc Natl Acad Sci U S A (2014) 111(29):10592–7.10.1073/pnas.1405546111
109
KusySGaultNFerriFLewandowskiDBarrocaVJaracz-RosAet alAdult hematopoiesis is regulated by TIF1γ, a repressor of TAL1 and PU.1 transcriptional activity. Cell Stem Cell (2011) 8(4):412–25.10.1016/j.stem.2011.02.005
110
MonteiroRPougetCPatientR. The gata1/pu.1 lineage fate paradigm varies between blood populations and is modulated by tif1γ. EMBO J (2011) 30(6):1093–103.10.1038/emboj.2011.34
111
GallouetASFerriFPetitVParcelierALewandowskiDGaultNet alMacrophage production and activation are dependent on TRIM33. Oncotarget (2017) 8(3):5111–22.10.18632/oncotarget.13872
112
WengLMitomaHTrichotCTricotCBaoMLiuYet alThe E3 ubiquitin ligase tripartite motif 33 is essential for cytosolic RNA-induced NLRP3 inflammasome activation. J Immunol (2014) 193(7):3676–82.10.4049/jimmunol.1401448
113
HowardPWRansomDGMaurerRA. Transcription intermediary factor 1gamma decreases protein expression of the transcriptional cofactor, LIM-domain-binding 1. Biochem Biophys Res Commun (2010) 396(3):674–8.10.1016/j.bbrc.2010.04.160
114
KulkarniAOzaJYaoMSohailHGinjalaVTomas-LobaAet alTripartite motif-containing 33 (TRIM33) protein functions in the poly(ADP-ribose) polymerase (PARP)-dependent DNA damage response through interaction with amplified in liver cancer 1 (ALC1) protein. J Biol Chem (2013) 288(45):32357–69.10.1074/jbc.M113.459164
115
OzaJGangulyBKulkarniAGinjalaVYaoMGanesanS. A novel role of chromodomain protein CBX8 in DNA damage response. J Biol Chem (2016) 291(44):22881–93.10.1074/jbc.M116.725879
116
XueJChenYWuYWangZZhouAZhangSet alTumour suppressor TRIM33 targets nuclear β-catenin degradation. Nat Commun (2015) 6:6156.10.1038/ncomms7156
117
HeslingCFattetLTeyreGJuryDGonzaloPLopezJet alAntagonistic regulation of EMT by TIF1γ and Smad4 in mammary epithelial cells. EMBO Rep (2011) 12(7):665–72.10.1038/embor.2011.78
118
IkeuchiYDadakhujaevSChandhokeASHuynhMAOldenborgAIkeuchiMet alTIF1γ protein regulates epithelial-mesenchymal transition by operating as a small ubiquitin-like modifier (SUMO) E3 ligase for the transcriptional regulator SnoN1. J Biol Chem (2014) 289(36):25067–78.10.1074/jbc.M114.575878
119
HerquelBOuararhniKDavidsonI. The TIF1α-related TRIM cofactors couple chromatin modifications to transcriptional regulation, signaling and tumor suppression. Transcription (2011) 2(5):231–6.10.4161/trns.2.5.17725
120
HerquelBOuararhniKKhetchoumianKIgnatMTeletinMMarkMet alTranscription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma. Proc Natl Acad Sci U S A (2011) 108(20):8212–7.10.1073/pnas.1101544108
121
AucagneRDroinNPaggettiJLagrangeBLargeotAHammannAet alTranscription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J Clin Invest (2011) 121(6):2361–70.10.1172/JCI45213
122
VincentDFYanKPTreilleuxIGayFArfiVKaniewskiBet alInactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet (2009) 5(7):e1000575.10.1371/journal.pgen.1000575
123
VincentDFGoutJChuvinNArfiVPommierRMBertolinoPet alTif1γ suppresses murine pancreatic tumoral transformation by a Smad4-independent pathway. Am J Pathol (2012) 180(6):2214–21.10.1016/j.ajpath.2012.02.006
124
LigrMWuXDanielsGZhangDWangHHajduCet alImbalanced expression of Tif1γ inhibits pancreatic ductal epithelial cell growth. Am J Cancer Res (2014) 4(3):196–210.
125
DingZYJinGNWangWChenWXWuYHAiXet alReduced expression of transcriptional intermediary factor 1 gamma promotes metastasis and indicates poor prognosis of hepatocellular carcinoma. Hepatology (2014) 60(5):1620–36.10.1002/hep.27273
126
JingushiKUedaYKitaeKHaseHEgawaHOhshioIet almiR-629 targets TRIM33 to promote TGFβ/Smad signaling and metastatic phenotypes in ccRCC. Mol Cancer Res (2015) 13(3):565–74.10.1158/1541-7786.MCR-14-0300
127
WangLYangHLeiZZhaoJChenYChenPet alRepression of TIF1γ by SOX2 promotes TGF-β-induced epithelial-mesenchymal transition in non-small-cell lung cancer. Oncogene (2016) 35(7):867–77.10.1038/onc.2015.141
128
KassemLDeygasMFattetLLopezJGoulventTLavergneEet alTIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients. BMC Cancer (2015) 15:453.10.1186/s12885-015-1471-y
129
JainSSinghalSFrancisFHajduCWangJHSuriawinataAet alAssociation of overexpression of TIF1γ with colorectal carcinogenesis and advanced colorectal adenocarcinoma. World J Gastroenterol (2011) 17(35):3994–4000.10.3748/wjg.v17.i35.3994
130
TakahashiKYoshidaNMurakamiNKawataKIshizakiHTanaka-OkamotoMet alDynamic regulation of p53 subnuclear localization and senescence by MORC3. Mol Biol Cell (2007) 18(5):1701–9.10.1091/mbc.E06-08-0747
131
MimuraYTakahashiKKawataKAkazawaTInoueN. Two-step colocalization of MORC3 with PML nuclear bodies. J Cell Sci (2010) 123(Pt 12):2014–24.10.1242/jcs.063586
132
HeFUmeharaTSaitoKHaradaTWatanabeSYabukiTet alStructural insight into the zinc finger CW domain as a histone modification reader. Structure (2010) 18(9):1127–39.10.1016/j.str.2010.06.012
133
BicoccaVTChangBHMasoulehBKMuschenMLoriauxMMDrukerBJet alCrosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell (2012) 22(5):656–67.10.1016/j.ccr.2012.08.027
134
JadhavGTeguhDKennyJTicknerJXuJ. Morc3 mutant mice exhibit reduced cortical area and thickness, accompanied by altered haematopoietic stem cells niche and bone cell differentiation. Sci Rep (2016) 6:25964.10.1038/srep25964
135
QiuZYuanWChenTZhouCLiuCHuangYet alHMGCR positively regulated the growth and migration of glioblastoma cells. Gene (2016) 576(1 Pt 1):22–7.10.1016/j.gene.2015.09.067
136
LarssonO. HMG-CoA reductase inhibitors: role in normal and malignant cells. Crit Rev Oncol Hematol (1996) 22(3):197–212.10.1016/1040-8428(96)00193-X
137
MoHElsonCE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) (2004) 229(7):567–85.10.1177/153537020422900701
138
ClendeningJWPandyraABoutrosPCEl GhamrasniSKhosraviFTrentinGAet alDysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A (2010) 107(34):15051–6.10.1073/pnas.0910258107
139
ButtSButtTJirströmKHartmanLAminiRMZhouWet alThe target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy. Ann Surg Oncol (2014) 21(9):2911–9.10.1245/s10434-014-3708-4
140
ChushiLWeiWKangkangXYongzengFNingXXiaoleiC. HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells. Gene (2016) 587(1):42–7.10.1016/j.gene.2016.04.029
141
SinghRYadavVKumarSSainiN. MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1. Sci Rep (2015) 5:17454.10.1038/srep17454
142
BlankCUHaanenJBRibasASchumacherTN. Cancer immunology. The “cancer immunogram”. Science (2016) 352(6286):658–60.10.1126/science.aaf2834
143
PandyaPHMurrayMEPollokKERenbargerJL. The immune system in cancer pathogenesis: potential therapeutic approaches. J Immunol Res (2016) 2016:4273943.10.1155/2016/4273943
144
BenvenisteODrouotLJouenFCharuelJLBloch-QueyratCBehinAet alCorrelation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum (2011) 63(7):1961–71.10.1002/art.30344
145
DrouotLAllenbachYJouenFCharuelJLMartinetJMeyerAet alExploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies. Arthritis Res Ther (2014) 16(1):R39.10.1186/ar4468
146
AggarwalROddisCVGoudeauDKoontzDQiZReedAMet alAutoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology (Oxford) (2016) 55(6):991–9.10.1093/rheumatology/kev444
147
Arouche-DelapercheLAllenbachYAmelinDPreusseCMoulyVMauhinWet alPathogenic role of anti-SRP and anti-HMGCR antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Ann Neurol (2017) 81(4):538–48.10.1002/ana.24902
148
MohasselPRosenPCasciola-RosenLPakKMammenAL. Expression of the dermatomyositis autoantigen transcription intermediary factor 1γ in regenerating muscle. Arthritis Rheumatol (2015) 67(1):266–72.10.1002/art.38863
Summary
Keywords
cancer, myositis, autoimmunity, TIF1gamma, autoantibody
Citation
Aussy A, Boyer O and Cordel N (2017) Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer. Front. Immunol. 8:992. doi: 10.3389/fimmu.2017.00992
Received
23 June 2017
Accepted
03 August 2017
Published
21 August 2017
Volume
8 - 2017
Edited by
Massimo Gadina, National Institute of Arthritis and Musculoskeletal and Skin Diseases, United States
Reviewed by
Silvia Brunelli, University of Milano-Bicocca, Italy; Juerg Hamacher, Lindenhof Hospital, Switzerland
Updates
Copyright
© 2017 Aussy, Boyer and Cordel.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Olivier Boyer, olivier.boyer@chu-rouen.fr
Specialty section: This article was submitted to Inflammation, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.